Compare Stocks: BMGL, MGRX, GXAI, and AIDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.43 +0.2%	$0.65	$0.40 ▼ $50.00	$5.22M	N/A	566,496 shs	119,879 shs
BMGL Basel Medical Group	$5.76 +2.5%	$6.71	$4.60 ▼ $27.00	$8.79M	0.24	29,558 shs	1,591 shs
GXAI Gaxos.ai	$0.82 +8.9%	$1.14	$0.73 ▼ $2.96	$5.34M	0.94	262,877 shs	1.21 million shs
MGRX Mangoceuticals	$0.54 -3.8%	$0.41	$0.16 ▼ $2.75	$9.56M	2.09	30.15 million shs	14.91 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	0.00%	-13.42%	-30.88%	-72.49%	+42,509,900.00%
BMGL Basel Medical Group	0.00%	-2.94%	-32.69%	-16.37%	-76.82%
GXAI Gaxos.ai	0.00%	-29.25%	-35.34%	-41.41%	-33.92%
MGRX Mangoceuticals	0.00%	+6.99%	+18.53%	+75.30%	-67.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.43 +0.2%	$0.65	$0.40 ▼ $50.00	$5.22M	N/A	566,496 shs	119,879 shs
BMGL Basel Medical Group	$5.76 +2.5%	$6.71	$4.60 ▼ $27.00	$8.79M	0.24	29,558 shs	1,591 shs
GXAI Gaxos.ai	$0.82 +8.9%	$1.14	$0.73 ▼ $2.96	$5.34M	0.94	262,877 shs	1.21 million shs
MGRX Mangoceuticals	$0.54 -3.8%	$0.41	$0.16 ▼ $2.75	$9.56M	2.09	30.15 million shs	14.91 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	0.00%	-13.42%	-30.88%	-72.49%	+42,509,900.00%
BMGL Basel Medical Group	0.00%	-2.94%	-32.69%	-16.37%	-76.82%
GXAI Gaxos.ai	0.00%	-29.25%	-35.34%	-41.41%	-33.92%
MGRX Mangoceuticals	0.00%	+6.99%	+18.53%	+75.30%	-67.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIDX 20/20 Biolabs	2.00	Hold	$5.00	1,074.26% Upside
BMGL Basel Medical Group	1.00	Sell	N/A	N/A
GXAI Gaxos.ai	1.00	Sell	N/A	N/A
MGRX Mangoceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BMGL, MGRX, GXAI, and AIDX Analyst Ratings

Date	Company	Brokerage	Action	Rating
7/31/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/30/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/30/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	MGRX Mangoceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/15/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/12/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/29/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/28/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/14/2026	AIDX 20/20 Biolabs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIDX 20/20 Biolabs	$1.84M	2.83	N/A	N/A	N/A	∞
BMGL Basel Medical Group	$8.90M	1.01	N/A	N/A	$2.44 per share	2.36
GXAI Gaxos.ai	$1.93M	3.01	N/A	N/A	$1.79 per share	0.46
MGRX Mangoceuticals	$460K	20.01	N/A	N/A	$0.93 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIDX 20/20 Biolabs	N/A	-$0.28	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	-$9.50M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	-$3.90M	-$0.63	N/A	N/A	N/A	-131.28%	-34.42%	-33.12%	8/12/2026 (Estimated)
MGRX Mangoceuticals	-$20.64M	-$1.49	N/A	N/A	N/A	-4,639.13%	-112.00%	-104.96%	N/A

Latest BMGL, MGRX, GXAI, and AIDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	N/A	GXAI Gaxos.ai	-$0.15	N/A	N/A	N/A	$1.80 million	N/A
6/26/2026	Q2 2026	BMGL Basel Medical Group	N/A	$0.01	N/A	$0.0050	N/A	$3.21 million
5/20/2026	Q1 2026	AIDX 20/20 Biolabs	N/A	-$0.28	N/A	-$0.28	N/A	$0.35 million
5/19/2026	Q1 2026	MGRX Mangoceuticals	N/A	-$0.22	N/A	-$0.22	N/A	$0.07 million
5/14/2026	Q1 2026	GXAI Gaxos.ai	-$0.20	-$0.25	-$0.05	-$0.25	$1.60 million	$1.81 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIDX 20/20 Biolabs	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	N/A	N/A	N/A	N/A	N/A
MGRX Mangoceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIDX 20/20 Biolabs	N/A	N/A	N/A
BMGL Basel Medical Group	0.93	1.88	1.83
GXAI Gaxos.ai	N/A	21.37	21.37
MGRX Mangoceuticals	N/A	0.29	0.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIDX 20/20 Biolabs	N/A
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	42.62%
MGRX Mangoceuticals	56.72%

Insider Ownership

Company	Insider Ownership
AIDX 20/20 Biolabs	29.80%
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	3.17%
MGRX Mangoceuticals	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIDX 20/20 Biolabs	14	12.25 million	N/A	N/A
BMGL Basel Medical Group	36	1.56 million	N/A	N/A
GXAI Gaxos.ai	3	7.12 million	6.90 million	N/A
MGRX Mangoceuticals	3	17.17 million	14.42 million	Not Optionable

BMGL, MGRX, GXAI, and AIDX Headlines

Recent News About These Companies

MGRX surges after Nuclea Energy reverse-merger deal reshapes company story

July 31 at 11:11 AM | quiverquant.comQ

Mangoceuticals (MGRX) stock jumps 138% after hours on nuclear reactor deal: Here's why it is trending

July 31 at 5:41 AM | msn.com

Mangoceuticals, Inc.: Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

July 30, 2026 | finanznachrichten.de

Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor

July 30, 2026 | newsfilecorp.comN

Mangoceuticals Announces Nuclea Energy Business Combination Agreement

July 30, 2026 | tipranks.com

Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology

July 30, 2026 | globenewswire.com

Mangoceuticals (NASDAQ:MGRX) Stock Rating Upgraded by Wall Street Zen

July 25, 2026 | americanbankingnews.com

Mangoceuticals Stock Short Interest Report | NASDAQ:MGRX | Benzinga

July 17, 2026 | benzinga.com

MGRX Share News Today

July 9, 2026 | uk.investing.com

Mangoceuticals Raises Capital via Private Equity Placement

July 2, 2026 | tipranks.com

Mangoceuticals Stock Price History

June 24, 2026 | investing.com

Mangoceuticals Inc

May 29, 2026 | money.usnews.com

Mangoceuticals Inc.

May 18, 2026 | marketwatch.com

Mangoceuticals Delays Quarterly Filing After Audit Review

May 15, 2026 | tipranks.com

Mangoceuticals Insider Trading Activity | NASDAQ:MGRX | Benzinga

April 13, 2026 | benzinga.com

Mangoceuticals Delays Annual 10-K Yearly Filing

March 31, 2026 | tipranks.com

Mangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity ...

March 23, 2026 | finanznachrichten.de

Mangoceuticals (MGRX) Stock Rockets 130% Following CEO’s Substantial Share Award

March 23, 2026 | blockonomi.com

Why Is Mangoceuticals, Inc. Stock (MGRX) Up Today?

March 23, 2026 | tipranks.com

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

March 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL, MGRX, GXAI, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

$0.43 +0.00 (+0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 0.00 (-1.13%)

As of 07:57 PM Eastern

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.

Basel Medical Group NASDAQ:BMGL

$5.76 +0.14 (+2.47%)

Closing price 03:56 PM Eastern

Extended Trading

$5.90 +0.14 (+2.45%)

As of 07:37 PM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Gaxos.ai NASDAQ:GXAI

$0.82 +0.07 (+8.87%)

Closing price 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.53%)

As of 07:50 PM Eastern

Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.

Mangoceuticals NASDAQ:MGRX

$0.54 -0.02 (-3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.49 -0.05 (-8.77%)

As of 07:59 PM Eastern

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMGL, MGRX, GXAI, and AIDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMGL, MGRX, GXAI, and AIDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMGL, MGRX, GXAI, and AIDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL, MGRX, GXAI, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMGL, MGRX, GXAI, and AIDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMGL, MGRX, GXAI, and AIDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMGL, MGRX, GXAI, and AIDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMGL, MGRX, GXAI, and AIDX Company Descriptions

20/20 Biolabs NASDAQ:AIDX

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

Mangoceuticals NASDAQ:MGRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools